PMID- 15290460
OWN - NLM
STAT- MEDLINE
DCOM- 20040927
LR  - 20180509
IS  - 1341-321X (Print)
IS  - 1341-321X (Linking)
VI  - 10
IP  - 3
DP  - 2004 Jun
TI  - The activity of grepafloxacin in two murine models of Mycobacterium avium 
      infection.
PG  - 185-8
AB  - The activity against Mycobacterium avium complex (MAC) of varying doses of 
      grepafloxacin (GRE; 25 mg/kg, 50 mg/kg, 100 mg/kg, and 200 mg/kg) were compared 
      to clarithromycin (CLA; 100 mg/kg and 200 mg/kg), ethambutol (EMB; 100 mg/kg), 
      and rifabutin (RBT; 10 mg/kg) using an intranasal (IN) infection model compared 
      to an intravenous (IV) infection model. Beige mice (C57BL6/J-Lyst bg J/+) were 
      infected intranasally with about 10(6) organisms and for the IV model about 10(7) 
      organisms. Treatment for both models was started 1 week postinfection and given 
      by gavage 5 days/week for 4 weeks. At the initiation of therapy, an early control 
      group was killed to determine the initial organism load. Three days following the 
      completion of therapy, drug-treated groups of mice and the late control group 
      were killed and the response to therapy measured. The most effective agents were 
      CLA and RBT. GRE and EMB had modest activities in both the IN and the IV models. 
      A matched comparison between IN and IV challenges for each of the agents used 
      revealed greater suppression of MAC in the IN model compared to the IV model.
FAU - Cynamon, Michael H
AU  - Cynamon MH
AD  - Department of Medicine, VA Medical Center, Syracuse, NY 13210, USA. 
      michael.cynamon@med.va.gov
FAU - Sklaney, Mary
AU  - Sklaney M
FAU - Yeo, Anthony E T
AU  - Yeo AE
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Netherlands
TA  - J Infect Chemother
JT  - Journal of infection and chemotherapy : official journal of the Japan Society of 
      Chemotherapy
JID - 9608375
RN  - 0 (Fluoroquinolones)
RN  - 0 (Piperazines)
RN  - 1W306TDA6S (Rifabutin)
RN  - 8G167061QZ (Ethambutol)
RN  - H1250JIK0A (Clarithromycin)
RN  - L1M1U2HC31 (grepafloxacin)
SB  - IM
MH  - Administration, Intranasal
MH  - Animals
MH  - Clarithromycin/administration & dosage/pharmacology
MH  - Disease Models, Animal
MH  - Ethambutol/administration & dosage/pharmacology
MH  - Female
MH  - Fluoroquinolones/administration & dosage/*pharmacology
MH  - Injections, Intravenous
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Microbial Sensitivity Tests
MH  - Mycobacterium avium Complex/*drug effects
MH  - Piperazines/administration & dosage/*pharmacology
MH  - Random Allocation
MH  - Rifabutin/administration & dosage/pharmacology
EDAT- 2004/08/04 05:00
MHDA- 2004/09/28 05:00
CRDT- 2004/08/04 05:00
PHST- 2003/09/01 00:00 [received]
PHST- 2004/04/27 00:00 [accepted]
PHST- 2004/08/04 05:00 [pubmed]
PHST- 2004/09/28 05:00 [medline]
PHST- 2004/08/04 05:00 [entrez]
AID - S1341-321X(04)71071-5 [pii]
AID - 10.1007/s10156-004-0316-4 [doi]
PST - ppublish
SO  - J Infect Chemother. 2004 Jun;10(3):185-8. doi: 10.1007/s10156-004-0316-4.